BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generatingnew drug candidates to fuel the Company’s own broad clinical development pipeline or for additional licensing and partnering. Currently, the company has five clinical programs for hematological cancer and solid tumor treatment.[1] Furthermore, the company has a fully integrated, proprietary, state-of-the art manufacturing facility unit. Martin Welschof has been CEO since 2018.[2][3][4][5][6][7] The company is a partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program, an initiative that develops blood cancer treatment.[8]

References

  1. ↑ "BioInvent Issues Statement Confirming that it does not Hold Cash Deposits or Securities at Silicon Valley Bank". Yahoo Finance. 13 March 2023. Retrieved 2023-03-21.
  2. ↑ "BioInvent rekryterar Martin Welschof som ny vd" (press release), Cision, 12 April 2018 (in Swedish).
  3. ↑ "BioInvent International", Avanza Bank, retrieved 19 June 2019 (in Swedish).
  4. ↑ "Technology", Bioinvent, retrieved 19 June 2019.
  5. ↑ Kajsa-Stina Kalin, "Bioinvent var pionjärer i parken" Sydsvenskan, 4 October 2015 (in Swedish).
  6. ↑ Maria Lindh, "Forskningen som ledde till miljardavtalet" Archived 2019-06-02 at the Wayback Machine, LUM., Lund University, 11 September 2015 (in Swedish).
  7. ↑ "Bioinvent i nytt cancer–samarbete", Dagens Nyheter, 4 January 2012 (in Swedish; subscription required).
  8. ↑ Cornall, Jim (2023-01-18). "BioInvent receives funding for blood cancer treatments". Labiotech.eu. Retrieved 2023-03-21.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.